Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression

Prostate

Volumn 59, Issue 4, 2004, Pages 401-408

  Hobisch, Alfred ^a,d   Fiechtl, Matthias ^a   Sandahl Sorensen, Boe ^c   Godoy Tundidor, Sonia ^a   Artner Dworzak, Erika ^b   Ramoner, Reinhold ^a   Bartsch, Georg ^a   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d General Hospital Feldkirch   (Austria)

Author keywords

Endocrine therapy; Epidermal growth factor; Prostate cancer; Tumor model

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 2442713887     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10372     Document Type: Article

References (31)

1. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54:1566-1573.
2. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999;179:336-346.
3. Culig Z, Hoffmann J, Erdel M, Eder I, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242-251.
4. Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Intermittent androgen suppression in prostate cancer: The Canadian experience. Urology 2002;60:52-56.
5. Hobisch A, Hoffmann J, Lambrinidis L, Eder I, Bartsch G, Klocker H, Culig Z. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide in a new prostate cancer model. Urol Int 2000;65:73-79.
6. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992;65:177-182.
7. Gioeli D, Mandell JW, Petroni GR, Frierson HFJ, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284.
8. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003;63:1975-1980.
9. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1978;72:248-254.
10. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin Cancer Res 2001;7:2941-2948.
11. Christensen B, Kieler J, Vilien M, Don P, Wang CY, Wolf H. A classification of human urothelial cells propagated in vitro. Anticancer Res 1984;4:319-337.
12. Seth D, Shaw K, Jazayeri J, Leedman PJ. Complex posttranscriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999; 80:657-669.
13. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-2790.
14. Connolly JM, Rose DP. Production of epidermal growth factor and transforming growth factor alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 1990;16:209-218.
15. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992; 52:571-577.
16. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
17. Torring N, Dagnaes-Hansen F, Sandahl Sorensen B, Nexo E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 2003;56:142-149.
18. Schuurmans ALG, Bolt J, Voorhorst M, Blankenstein RA, Mulder E. Regulation of growth and epidrmal growth factor receptor levels of LNCaP prostatic tumor cells by different steroids. Int J Cancer 1988;42:917-922.
19. Ravenna L, Lubrano C, DiSilverio F, Vacca A, Felli MP, Maroder M, D'Eramo G, Sciarra F, Frati L, Gulino A. Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate 1995;26:290-298.
20. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy 2000;7:997-1007.
21. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cells expressing the human androgen receptor. Cancer Res 1995;55:3197-3203.
22. Sherwood ER, van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C. Epidermal growth factor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998;77:855-861.
23. Liu XH, Wiley HS, Meikle AW. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab 1993;77:1472-1478.
24. Noguchi S, Ohba Y, Oka T. Pretranslational enhancement of epidermal growth factor receptor by direct effect of testosterone in mouse liver. Endocrinology 1991;128:2141-2148.
25. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB EGF), amphiregulin, TGF alpha, and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-95.
26. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-285.
27. Sehgal I, Bailey J, Hitzemann K, Pittelkow MR, Maihle NJ. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells. Mol Biol Cell 1994;5:339-347.
28. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-1044.
29. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes JE, Macoska JA. Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 1994;25:199-205.
30. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-550.
31. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentis M, De Placido S, Catalano G, Bianco G, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.